Baxter International is a healthcare company that focuses on developing and providing a wide range of medical products and services to enhance patient care. The company specializes in creating innovative therapies and solutions for various health conditions, including renal and hospital care. With a strong emphasis on sustainability and improving patient outcomes, Baxter manufactures essential medical devices, pharmaceuticals, and biotechnology products that support the treatment of chronic diseases and acute medical conditions. Their commitment to research and development drives advancements in healthcare technology, helping to meet the needs of healthcare professionals and patients worldwide. Read More
Date: February 11, 2026 Introduction In the first few weeks of 2026, a singular healthcare name has dominated the screens of institutional traders and retail investors alike: DaVita Inc. (NYSE: DVA). Once viewed with skepticism in late 2023 as the "Ozempic era" threatened to upend chronic kidney disease (CKD) management, DaVita has staged a remarkable [...]
Becton, Dickinson and Company (NYSE: BDX), widely known as BD, has long been a cornerstone of the global healthcare infrastructure. However, as of February 11, 2026, the company is making headlines not for its traditional stability, but for a radical transformation that has sent shockwaves through the market. Following the official completion of the multi-billion [...]
Today, February 9, 2026, marks a watershed moment for Becton, Dickinson and Company (NYSE: BDX). The medical technology giant, commonly known as BD, has officially closed its transformative $17.5 billion combination with Waters Corporation (NYSE: WAT), effectively spinning off its Biosciences and Diagnostic Solutions units to create a more streamlined "New BD." Simultaneously, the company [...]
Baxter International Inc. (NYSE:BAX), a leading global medtech company, will host a conference call to discuss its fourth-quarter 2025 financial results on Thursday, February 12, 2026 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I81994118 to pre-register for the call and receive the call information.
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks.
But their headline prices don’t guarantee quality, and investors should exercise caution as some have shaky business models.
Baxter International Inc. (NYSE:BAX), an innovator in smart beds for med-surg and the intensive care unit, announced at the 2026 J.P. Morgan Healthcare Conference the upcoming U.S. launch of the Dynamo Series stretcher. The Dynamo Series is a stretcher designed to help alleviate the physical and cognitive burden on care teams1 and make it easier for them to focus on patient care, while improving the patient’s experience. Intended for use in emergency departments, perioperative environments and patient transport services, the Dynamo Series is the latest innovation in Baxter’s leading portfolio of smart beds, surfaces and connected care solutions.
Shares of healthcare company Baxter International (NYSE:BAX)
fell 4.5% in the afternoon session after Barclays lowered its price target on the stock to $30 from $36, signaling a more cautious outlook on the company.
MUSC Health and Baxter International Inc. (NYSE:BAX), a global medtech leader, are entering into a multi-year strategic partnership that aims to enhance the high-quality and safe patient care already delivered at MUSC Health, MUSC’s health care system, through integrated connected care technologies.
Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12, 2026. Andrew Hider, Baxter’s president and chief executive officer, is scheduled to present at 2:15 p.m. Pacific Time.
As of December 26, 2025, Baxter International Inc. (NYSE: BAX) stands at a pivotal crossroads in its nearly century-long history. Long considered a defensive "blue-chip" staple of the healthcare sector, Baxter spent much of the early 2020s grappling with the massive debt from its $10.5 billion acquisition of Hillrom, supply chain fragilities exposed by the [...]
NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors Baxter International, Inc. (NYSE: BAX) and Molina Healthcare, Inc. (NYSE: MOH) on behalf of long-term stockholders. More information about each potential case can be found at the link provided.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Baxter (BAX) To Contact Him Directly To Discuss Their Options
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Baxter International Inc. (“Baxter” or “the Company”) (NYSE: BAX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
